ClinicalTrials.gg
RecruitingNCT05739084RADIOSARCUpdated Feb 22, 2023

Gene Signatures Searching of Sensitivity/Resistance to Neoadjuvant Radiotherapy in Patients With Resectable STS

An observational study in Soft Tissue Sarcomas, sponsored by Centre Leon Berard. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-22.

Sponsored by Centre Leon Berard · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Sarcoma by Centre Leon Berard — 4 open to participants now, 8 under way, 1 of them phase 3. Sarcoma · Centre Leon Berard.

Started
2022
with 1 other
Observational
4 of 16
1 open now
Registered
13th of 16
by date

Among the 16 studies in Sarcoma by Centre Leon Berard, this one is one of 2 that started in 2022, is one of 4 observational ones, and was the 13th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

4 of the 16 studies in Sarcoma by Centre Leon Berard are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Sarcoma by Centre Leon Berard, or all of them as a file.
02

Study summary

To date, the radiation oncologist are missing biomarkers predictive of response/resistance to RT in order to identify patients who may benefit from RT and personalize the RT schedule. Our proposal is to conduct a cohort study aiming at identifying transcriptomic biomarkers predictive of sensitivity and/or resistance to RT in limbs STS patients

Read the detailed description

Whether RT should be performed pre or post-operatively is still a debated question. To date, the radiation oncologist are missing signature of response/resistance to RT in order to identify patients who may benefit from RT and personalize the RT schedule. Therefore, predicting the likelihood of response/resistance to RT is essential. The individual exploration with high-throughput approaches will participate in describing biological mechanisms involved in STS tumor cell pan-resistance, thus identifying potential molecular targets that could be inhibited to reverse intrinsic radioresistance. In this context, our proposal is to conduct a cohort study aiming at identifying transcriptomic signature predictive of sensitivity and/or resistance to RT in limbs STS patients.

03

Conditions studied

  • Soft Tissue Sarcomas

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with Soft tissus sarcoma who underwent/undergo to preoperative Radiation and for whom resected tumour specimen is available.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female ≥ 18 years at time of non-opposition to participate to the study
  • Patient with documented non-opposition to participate to the study.
  • Patient with and cytologically confirmed diagnosis with STS (..)
  • Patient with availability of FFPE tumor block from initial diagnosis (mandatory) and surgery specimen (optional).
  • Patients with tumor FFPE samples prepared with the last 4 years
  • Patient with evaluable tumor sample meeting the following quality/quantity control criteria (..)

Exclusion criteria

Exclusion Criteria:

  • Patients with soft tissue sarcoma at diagnosis
  • Patients with exclusive radiotherapy without surgical resection
  • Patients receiving neo systemic treatment (chemotherapy, immunotherapy, targeted therapy)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Retrospective cohort

    A total sample size of 200 patients is expected in the retrospective thanks to the NETSARC/ CONTICABASE databases (French sarcoma reference network)

    Radiation: pre-operative radiation · Procedure: Standard surgery after rpreoprative radiation

  • Prospective cohort

    To ensure an external validation, patients from NETsarc centers experiencing preoperative RT will be prospectively accrued and transcriptomic signature will be tested. Up to 100 patients will be enrolled in this prospective cohort.

    Radiation: pre-operative radiation · Procedure: Standard surgery after rpreoprative radiation

Interventions

  • Radiationpre-operative radiation

    As per standard of care and institutional guidelines

  • ProcedureStandard surgery after rpreoprative radiation

    As per standard of care and institutional guidelines

06

What researchers measure

Primary outcomes

  1. To define a transcriptomic signature of histological response to radiotherapy in STS patients using the percentage of residual viable cells as a clinical meaningful endpoint

    Gene expression signature using RNAseq correlated to the percentage of residual viable cells on surgery specimen to define histological response.

    Time frame: 36 months

Secondary outcomes

  1. To identify biomarkers of sensitivity or resistance to radiotherapy in STS patients using additional clinical endpoints

    Gene expression signature using RNAseq correlated to the percentage of necrosis, the percentage of fibrosis, the local control at 1 and 2 years (1- and 2-year local / distant recurrence-free survival, the time To Relapse (TTR), the Disease Free Survival (DFS), The Quality of resection level based on the residual tumor (R) classification.

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jun 2025, 31 months after the start.

Of 88 non-industry observational studies under Sarcoma, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 294. This study's planned 31 months is below that.

Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 42 and three quarters within 294.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2023
First posted
Feb 22, 2023
StartActual
Nov 23, 2022
Primary completionEst.
Jun 23, 2025
CompletionEst.
Nov 23, 2025
Last update
Feb 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05739084
Lead sponsor
Centre Leon Berard
Responsible party
Sponsor
First posted
Feb 22, 2023
Start date
Nov 23, 2022
Primary completion
Jun 23, 2025 (estimated)
Completion
Nov 23, 2025 (estimated)
Last update
Feb 22, 2023

Study contacts

Marie -Pierre SUNYACH, MD
Contact
MariePierre.SUNYACH@lyon.unicancer.fr
+33(0)4 78 78 28 28
Waisse Waissi, MD
Contact
Waisse.WAISSI@lyon.unicancer.fr
+33(0)4 78 78 28 28

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion